Population-based incidence of human metapneumovirus infection among hospitalized children
- PMID: 20446850
- PMCID: PMC2873123
- DOI: 10.1086/652782
Population-based incidence of human metapneumovirus infection among hospitalized children
Abstract
Background: Human metapneumovirus (HMPV) is a leading cause of acute respiratory illness (ARI) in children. Population-based incidence rates and comprehensive clinical characterizations of disease have not been established.
Methods: We conducted population-based prospective surveillance for 2 years in 2 US counties of HMPV infection among children <5 years old who were hospitalized with ARI or fever. Nasal and throat specimens obtained with swabs were tested for HMPV by real-time reverse-transcription polymerase chain reaction and genotyped.
Results: Forty-two (3.8%) of 1104 children tested positive for HMPV. The overall annual rate of HMPV-associated hospitalizations per 1000 children <5 years old was 1.2 (95% confidence interval [CI], 0.9-1.6). This rate was highest among infants 0-5 months old (4.9 per 1000 [95% CI, 2.9-7.2]), followed by children 6-11 months old (2.9 per 1000 [95% CI, 1.4-4.7]). The annual rate of hospitalization for HMPV infection was less than that for respiratory syncytial virus infection but similar to that for influenza and parainfluenza virus 3 infection in all age groups. The mean age of children hospitalized with HMPV infection was 6 months. Bronchiolitis, pneumonia, and asthma were the most common diagnoses among children with HMPV infection. All 4 HMPV subgroups were detected during both years at both sites. HPMV infection was most prominent from March through May.
Conclusion: HMPV was detected in 3.8% of children hospitalized with ARI or fever, with a population incidence similar to that of influenza virus and parainfluenza virus 3.
Conflict of interest statement
Potential conflicts of interest: J.V.W. has served as a consultant for MedImmune and Novartis. K.M.E. receives research funding from Sanofi-Pasteur, Wyeth, Novartis, and CSL. G.A.W. has served as a consultant for MedImmune. M.R.G. has received research funding from MedImmune and Merck. C.B.H. has served as a consultant for and received research support from MedImmune. J.E.C. has served as a consultant for Anaptys, Immunobiosciences, Mapp, MedImmune, and Novartis and has received research support from MedImmune, Mapp, Alnylam, and Sanofi-Pasteur. C.K.W., C.-F.Y., D.S., D.Y., and R.R.S. were employees of MedImmune at the time of this study. All other authors report no potential conflicts.
Figures
Comment in
-
Human metapneumovirus infection as an emerging pathogen causing acute respiratory distress syndrome.J Infect Dis. 2011 Jan 15;203(2):294-5; author reply 296. doi: 10.1093/infdis/jiq045. J Infect Dis. 2011. PMID: 21288832 Free PMC article. No abstract available.
References
-
- McAdam AJ, Hasenbein ME, Feldman HA, et al. Human metapneumovirus in children tested at a tertiary-care hospital. J Infect Dis. 2004;190:20–26. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
